ProCE Banner Activity

Phase II Study of Iptacopan Monotherapy for Paroxysmal Nocturnal Hemoglobinuria: A 12-Mo Analysis

Slideset Download
Conference Coverage
Iptacopan monotherapy lowered LDH levels ≥60% within 12 weeks in all patients with PNH in this phase II study.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation